Saccharomyces boulardii para Antibiotic-Associated Diarrhea (AAD)
AMultiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
Conclusão
Multiple meta-analyses show S. boulardii reduces AAD risk by 47-53% (RR 0.47). Most studied probiotic for AAD prevention with consistent positive results across antibiotic classes.
Key Study Findings
Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None
vs: None
Outcome: None
Efeito: None
None
População: Pediatric population
Review
Intestinal Dysbiosis: Exploring Definition, Associated Symptoms, and Perspectives for a Comprehensive Understanding - a Scoping …
Dose: None
vs: None
Outcome: None
Efeito: None
None
População: scoping review of intestinal dysbiosis definition, symptoms, and probiotic adjuvant therapy in adults and children
Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None
vs: None
Outcome: Clinical guideline recommendations for pediatric GI
Efeito: None
None
População: Pediatric patients with GI disorders
Observational Study
n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None
vs: None
Outcome: Probiotic prescribing habits of Italian PCPs
Efeito: L. rhamnosus GG used by 91.8%
None
População: Italian primary care pediatricians
Randomized Controlled Trial
n=564
20 weeks
Double-blind
High-dose Probiotic Mix of Lactobacillus spp., Bifidobacterium spp., Bacillus coagulans, and Saccharomyces boulardii to Prevent …
Dose: None
vs: Placebo
Outcome: Quality of life
Efeito: None
P < .001
População: None
Review
Clostridioides difficile Infections: Prevention and Treatment Strategies.
Dose: None
vs: None
Outcome: C. difficile infection treatment outcomes
Efeito: None
None
População: Patients with C. difficile infection
Key Statistics
25
Estudos
5000
Participantes
↑
Positive
A
Nota
Referenced Papers
Probiotics and antimicrobial …
2025
26 citações
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Review
Journal of gastroenterology …
2025
10 citações
Antibiotics (Basel, Switzerland)
2025
Boletin medico del …
2025
Open forum infectious …
2024
7 citações
Zhongguo dang dai …
2024
5 citações
Advances in experimental …
2024
2 citações
Therapeutic advances in …
2023
97 citações
Overview of systematic reviews of probiotics in the prevention and treatment of antibiotic-associated diarrhea in children.
Systematic Review
Frontiers in pharmacology
2023
20 citações
Cureus
2023
19 citações
Cureus
2023
5 citações
The Journal of …
2023
1 citações
Archivos argentinos de …
2022
23 citações
Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.
Review
World journal of …
2019
92 citações
Advances in experimental …
2019
17 citações
Frontiers in medicine
2018
450 citações
Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.
Systematic Review
PloS one
2018
205 citações
Pharmacological research
2018
132 citações
World journal of …
2018
52 citações
The American journal …
2018
46 citações
World journal of …
2017
68 citações
Journal of pediatric …
2016
233 citações
Clinical and experimental …
2016
82 citações
Open forum infectious …
2016
58 citações
Digestive diseases (Basel, …
2016
37 citações
The Cochrane database …
2015
233 citações
Antibiotics (Basel, Switzerland)
2015
104 citações
Journal of clinical …
2015
35 citações
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Review
Nutrition in clinical …
2015
31 citações
Nutricion hospitalaria
2015
5 citações
MMW Fortschritte der …
2014
14 citações
MMW Fortschritte der …
2014
3 citações
Expert opinion on …
2014
The American journal …
2012
104 citações
Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use.
Other
The American journal …
2012
5 citações
Medycyna wieku rozwojowego
2012
1 citações
Journal of clinical …
2011
432 citações
World journal of …
2010
512 citações
Journal for specialists …
2010
22 citações
Probiotics.
Review
American journal of …
2010
European journal of …
2009
91 citações
Current opinion in …
2009
82 citações
Advances in biochemical …
2008
535 citações
Journal of clinical …
2008
Probiotics.
Review
American family physician
2008
The Journal of …
2007
265 citações
The Cochrane database …
2007
The American journal …
2006
918 citações
Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials.
Meta-Analysis
CMAJ : Canadian …
2006
197 citações
Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea.
Review
Journal of clinical …
2006
112 citações
Medical science monitor …
2006
The American journal …
2001
648 citações
International journal of …
2000
181 citações
Clinical infectious diseases …
1998
346 citações
Anaerobe
1997
40 citações
Gastroenterology
1989
418 citações
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Dosagens Comumente Utilizadas
- general:
- 250-500 mg/day (equivalent to 5-10 billion CFU)
- aadprevention:
- 500 mg/day (start with antibiotic, continue 7 days after)
- cdiffprevention:
- 500 mg twice daily as adjunct to standard therapy
- travelersdiarrhea:
- 250-500 mg/day starting 5 days before travel
Limite superior: Well-tolerated up to 1,000 mg/day in clinical trials
Dosagens Estudadas em Pesquisas
| Dosagem | Duração | Efeito | N |
|---|---|---|---|
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | 279 |
| None | 20 weeks | Positive | 564 |
| None | -- | Positive | -- |
| None | 1 weeks | Positive | 47 |
| Various probiotic interventions | -- | Positive | -- |
Melhor horário: Can be taken with or without food; space 2 hours from antifungals
Safety & Side Effects
Efeitos Colaterais Relatados
- ⚠ Mild gas and bloating
- ⚠ Rare: fungemia in critically ill patients with central venous catheters
- ⚠ Thirst (yeast may increase water requirements)
- ⚠ Very rare: potential environmental contamination risk in ICU settings
Interações Conhecidas
- ● Antifungal medications (may kill S. boulardii, reducing effectiveness)
- ● Monoamine oxidase inhibitors (S. boulardii contains tyramine)
- ● Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)
Ingestão máxima tolerável: Well-tolerated up to 1,000 mg/day in clinical trials
Consulte sempre o seu profissional de saúde antes de iniciar qualquer suplemento.Sempre consulte seu profissional de saúde antes de iniciar qualquer suplemento.
Frequently Asked Questions
Does Saccharomyces boulardii help with Antibiotic-Associated Diarrhea (AAD)?
Based on 25 studies with 5,000 participants, there is strong evidence from multiple clinical trials that Saccharomyces boulardii may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is A (Strong Evidence).
How much Saccharomyces boulardii should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 25 peer-reviewed studies with 5,000 total participants. The overall direction of effect is positive.
Related Evidence
Outros ingredientes para Antibiotic-Associated Diarrhea (AAD)
Saccharomyces boulardii para outras condições
Aviso Legal da FDA: Estas declarações não foram avaliadas pela Food and Drug Administration. Os produtos e informações neste site não se destinam a diagnosticar, tratar, curar ou prevenir qualquer doença. As notas de evidência apresentadas são baseadas em nossa análise de pesquisas revisadas por pares publicadas e não constituem aconselhamento médico. Sempre consulte seu profissional de saúde antes de iniciar qualquer regime de suplementação.